BioCentriq Advances Its Cell Therapy Manufacturing with New Facility in Princeton, NJ

BioCentriq Expands Operations in Princeton, NJ

BioCentriq, a prominent player in the cell therapy contract development and manufacturing sphere, has announced the acquisition of a new manufacturing facility in Princeton, New Jersey. This strategic move is set to bolster their operational footprint and capabilities in the burgeoning cell therapy industry.

In this development, BioCentriq has entered into a long-term lease agreement for an advanced state-of-the-art facility. This facility will serve as the company’s new headquarters and is slated for an initial capital investment of $12 million dedicated to upgrading infrastructure, equipment, and business systems. The aim is to enhance BioCentriq's capacity to provide comprehensive service solutions, encompassing the entire lifecycle of cell therapy products, from development to manufacturing and quality control.

Spanning roughly 60,000 square feet, the new site is outfitted with six independent ISO 7 cleanrooms. These are equipped with cutting-edge manufacturing technology such as advanced bioreactors and automated cell processing systems, which allows for scalable production to meet the escalating global demand for innovative therapies. Additionally, the facility adheres to current Good Manufacturing Practice (GMP) regulatory standards to ensure high-quality outcomes.

BioCentriq’s Princeton facility not only signifies a crucial expansion but also complements the existing infrastructure in Newark, NJ. The Newark campus features its own ISO 7 cleanrooms and a fully integrated quality control laboratory, facilitating clinical GMP production alongside serving as a hub for specialized training aimed at fostering talent in the pharmaceutical and biotech sectors. This dual-location strategy is designed to enhance BioCentriq's regional manufacturing network.

In its expanded role, the company is poised to offer an extensive suite of services. These include everything from technology transfer to technical assessments, process development, GMP manufacturing, and quality control lot release. BioCentriq has proven experience with various cell therapy modalities, including T-cell therapies like CAR-T and TCR, as well as natural killer cell therapies, iPSC, and MSC-based products. They aim to expedite service timelines through their advanced LEAP™ manufacturing platform.

By offering a spectrum of solutions—from standardized platform options to fully customizable services—BioCentriq is committed to advancing personalized therapies with unrivaled precision and efficiency. Their aim is to empower clients to navigate the complexities of innovative cell product development successfully.

Syed T. Husain, Chairman and CEO of BioCentriq, stated, "Securing this facility marks a significant milestone in our growth and reinforces our mission to deliver high-quality, scalable manufacturing solutions for cell therapy innovators globally. This facility allows us to further support our clients in bringing life-changing therapies to patients and demonstrates our ongoing commitment to providing industry-leading manufacturing expertise."

Plans are already in motion for the capital investment to be completed with the facility becoming operational by the second quarter of 2025. Meanwhile, process and analytical services are expected to be available as early as Q1 2025. BioCentriq’s commitment to innovation in cell therapy manufacturing solidifies its leadership position in the industry, and the implications of these expansions will undoubtedly resonate throughout the healthcare landscape in the years to come.